2-hydroxy-2-methylpropionamidine hydrochloride | 3619-62-3

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-hydroxy-2-methylpropionamidine hydrochloride
• 英文别名: 2-hydroxy-2-methylpropanimidamide hydrochloride；2-hydroxy-2-methylpropanimidamide;hydrochloride
• CAS: 3619-62-3
• 化学式: C₄H₁₀N₂O*ClH
• 分子量: 138.597
• InChiKey: AILSXICMPBNRRH-UHFFFAOYSA-N

物化性质

• 熔点：
  280 °C

计算性质

• 辛醇/水分配系数(LogP)：
  0.12
• 重原子数：
  8
• 可旋转键数：
  1
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  70.1
• 氢给体数：
  4
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-hydroxy-2-methylpropionamidine hydrochloride 在 正丁基锂 、 二异丙胺 、 sodium hydride 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 反应 0.5h， 生成 N-({3-[3-(3-fluorophenyl)-3-oxopropanoyl]phenyl}sulfonyl)-2-hydroxy-2-methylpropanimidamide
  参考文献：
  名称：

  PROPANE-1,3-DION DERIVATIVE OR SALT THEREOF

  摘要：

  公开号：

  EP1864976B1

文献信息

• SUBSTITUTED PYRIDINE UREA COMPOUNDS
  申请人：Selness Shaun R.

  公开号：US20120142708A1

  公开（公告）日：2012-06-07

  The present disclosure provides pyridine urea compounds useful in the treatment of p38 kinase mediated diseases, such as lymphoma and auto-inflammatory disease, having the structure of Formula (I): wherein R 1 , R 2 , R 3 , R 4 , R 5 , V and W are as defined in the detailed description; pharmaceutical compositions comprising at least one of the compounds; and methods for treating p38 kinase mediated diseases using the compound.

  本公开提供了在治疗p38激酶介导的疾病（如淋巴瘤和自身免疫性疾病）中有用的吡啶脲化合物，其具有如下结构（I）： 其中R1、R2、R3、R4、R5、V和W如详细描述中所定义；包括至少一种该化合物的药物组合物；以及使用该化合物治疗p38激酶介导的疾病的方法。
• SUBSTITUTED PYRIMIDINONE-PHENYL-PYRIMIDINYL COMPOUNDS
  申请人：CONFLUENCE LIFE SCIENCES, INC.

  公开号：US20130143906A1

  公开（公告）日：2013-06-06

  The present disclosure provides pyrimidinone-phenyl-pyrimidinyl compounds useful in the treatment of p38 kinase mediated diseases, such as lymphoma and inflammatory disease, having the structure of Formula (I): wherein R 1 , R 2 , R 3 , R 4 and R 5 are as defined in the detailed description; pharmaceutical compositions comprising at least one of the compounds; and methods for treating p38 kinase mediated diseases using the compound.

  本公开提供了在治疗p38激酶介导的疾病（如淋巴瘤和炎症性疾病）中有用的嘧啶酮-苯基-嘧啶基化合物，其具有如下式（I）的结构： 其中R1、R2、R3、R4和R5如详细描述中所定义；包括至少一种该化合物的药物组合物；以及使用该化合物治疗p38激酶介导的疾病的方法。
• [EN] HYDROXYALKYL-SUBSTITUTED TRIAZOLE DERIVATIVES AND USES THEREOF<br/>[FR] DÉRIVÉS DE TRIAZOLE SUBSTITUÉS PAR HYDROXYALKYLE ET UTILISATIONS ASSOCIÉES
  申请人：BAYER PHARMA AG

  公开号：WO2018073144A1

  公开（公告）日：2018-04-26

  The present invention relates to novel 3-(hydroxyalkyl)-1,2,4-triazole derivatives, to processes for the preparation of such compounds, to pharmaceutical compositions containing such compounds, and to the use of such compounds or compositions for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of renal and/or cardiovascular diseases.

  本发明涉及新颖的3-(羟基烷基)-1,2,4-三唑衍生物，涉及制备这类化合物的方法，涉及含有这类化合物的药物组合物，以及涉及利用这类化合物或组合物治疗和/或预防疾病，特别是治疗和/或预防肾脏和/或心血管疾病。
• [EN] PROCESS, COMPOSITIONS, AND CRYSTALLINE FORMS OF SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS<br/>[FR] PROCÉDÉ, COMPOSITIONS ET FORMES CRISTALLINES DE COMPOSÉS PYRIDINONE-PYRIDINYLE SUBSTITUÉS
  申请人：ACLARIS THERAPEUTICS INC

  公开号：WO2021195475A1

  公开（公告）日：2021-09-30

  The present disclosure provides a crystalline form of the methyl/fluoro-pyridinyl-methoxy substituted pyridinone-pyridinyl compound of the structure: XRPD, TGA, and DSC data on the crystalline form, as well as methods preparing the crystalline form, including a multi-kilo scale preparation. Also provided are pharmaceutical compositions and methods of treating p38 mediated diseases, such as lymphoma and auto-inflammatory disease, including rheumatoid arthritis. and methods of maximizing the yield thereof comprising administering of the compound. Also provided is a method of maximizing the yield of said compound via a recycling procedure.

  本公开提供了一种结晶形式的甲基/氟吡啶基甲氧基取代的吡啶酮-吡啶基化合物，其结构为：提供了该结晶形式的XRPD、TGA和DSC数据，以及制备该结晶形式的方法，包括多千克级的制备。还提供了制药组合物和治疗p38介导的疾病的方法，例如淋巴瘤和自身免疫性疾病，包括类风湿性关节炎。提供了一种通过给予该化合物来最大化其产量的方法。还提供了一种通过回收程序来最大化该化合物产量的方法。
• Propane-1,3-dione derivative or salt thereof
  申请人：Astellas Pharma Inc.

  公开号：US07960562B2

  公开（公告）日：2011-06-14

  It is intended to provide a compound useful as a GnRH receptor antagonist. The inventors further investigated propane-1,3-dione derivatives. As a result, they confirmed that a compound having a benzene ring or a thiophene ring substituted with a group represented by —SO2—R3 in a propane-1,3-dione derivative having 2-(1,3-dihydro-2H-benzimidazol-2-ylidene) has an excellent GnRH receptor antagonistic effect and accomplished the present invention. Because the compound of the present invention has a potent GnRH receptor antagonistic effect, it is useful for the treatment of sex hormone-dependent diseases, particularly GnRH-related diseases. Further, because the compound of the present invention has an excellent metabolic stability in human and few drug interactions, therefore it has preferable characteristics as a pharmaceutical used for the above-mentioned diseases.

  本发明旨在提供一种作为GnRH受体拮抗剂有用的复合物。发明人进一步研究了丙酮酸1,3-二酮衍生物。结果，他们确认，在具有2-(1,3-二氢-2H-苯并咪唑-2-基亚胺基)的丙酮酸1,3-二酮衍生物中，苯环或噻吩环取代为—SO2—R3基团的化合物具有出色的GnRH受体拮抗效果，并完成了本发明。由于本发明化合物具有强效的GnRH受体拮抗作用，因此对于治疗性激素依赖性疾病，特别是GnRH相关疾病非常有用。此外，由于本发明化合物在人体内具有出色的代谢稳定性和少量药物相互作用，因此具有作为上述疾病用药物的优良特性。